Sheppard Mullin: ‘Never too early’ to align dealmaking with regulation; Aterian, Clearlake portcos in add-ons

Private equity’s healthcare investments are coming under regulatory scrutiny in the US.

20 August 2024•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.